Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek Nutritional Oils Addition To U.S. Infant Formulas Forthcoming

This article was originally published in The Tan Sheet

Executive Summary

FDA's long-awaited affirmation that Martek Biosciences' nutritional oils are generally recognized as safe came May 17, giving the firm an entry into the approximately $2 bil. U.S. infant formula market.
Advertisement

Related Content

Science-Based Ingredient Firms Spur Bullish Investors In Supplement Sector
Science-Based Ingredient Firms Spur Bullish Investors In Supplement Sector
Science-Based Ingredient Firms Spur Bullish Investors In Supplement Sector
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Martek Facility Expansion, Plant Acquisition To Address Production Needs
Roche Pipeline Focus Includes Cognitive, Cardiovascular Benefits
DHA/ARA Term Infant Formula Negative Findings Cast Doubt On Launches
Mead Enfamil Sales Buoy Bristol-Myers Nutritionals In Q2
Martek DHA/ARA Pregnancy/Nursing Benefits Research Underway

Topics

Advertisement
UsernamePublicRestriction

Register

PS092570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel